On this page
Study design
A 12-week randomized, double-blind, placebo-controlled trial tested 1 mg/day of scallop-derived plasmalogens in cognitively healthy Japanese adults aged 40 or older selected for below-average baseline verbal memory. Of 168 people screened, 68 were randomized and 66 analyzed. The primary outcome was standardized verbal memory on the Cognitrax battery.
Findings
At week 12, the estimated between-group difference favored the supplement by 10.1 points (95% CI 0.4–19.9; p=0.042). Selected attention measures also improved, but they were secondary outcomes. Plasma BDNF did not differ between groups. The verbal-memory result is a signal in a selected group for one formulation; it is not evidence of dementia prevention or a general cognitive benefit.
Limitations and disclosures
The sample was small and follow-up short; persistence and daily-life effects were not assessed. Repeated computerized testing may produce practice effects, and the confidence interval was wide. B&S Corporation funded the trial and supplied the test food; the paper says the funder had no role. One author was a B&S executive and shareholder, another a B&S employee, and another worked for recruiting CRO ORTHOMEDICO.
This sourced news summary and translation were prepared with AI assistance. Source links, the news date and research limitations are disclosed; this is not a claim of independent medical expert review. News production method.
Sources
Research news is not medical advice or a recommendation to use a substance. Read findings in the context of the study design, participants and limitations. Editorial standards.
← All news